System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Publications

Journal Article Epublish

PubMed: 41333222 DOI: 10.3389/fonc.2025.1648272

Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy.

Front Oncol 15:1648272

Authors: Ana Godoy-Ortíz, Gonzalo Lendínez-Sánchez, Manuel Zalabardo, Javier Pascual, Ana López-Pascual, Alexandra Cantero, Nuria Ribelles, Marcos Iglesias, Ester Villar, Bella Pajares, Tamara Díaz-Redondo, Maria Emilia Domínguez-Recio, Francisco Carabantes, Maria Jose Bermejo, Antonio Rueda-Domínguez, Emilio Alba, Alfonso Sánchez-Muñoz

Affiliations

  • Department of Medical Oncology, Virgen de La Victoria University Hospital, Malaga, Spain.
  • The Biomedical Research Institute of Malaga (IBIMA-CIMES-UMA), Malaga, Spain.
  • Centro de Investigacion Biomedica en Red de Cáncer (CIBERONC-CB16/12/00481), Madrid, Spain.
  • Department of Medical Oncology, Hospital Regional Universitario de Malaga, Malaga, Spain.
  • The Biomedical Research Institute of Malaga (IBIMA-CIMES-UMA), Malaga, Spain. Department of Medical Oncology, Hospital Regional Universitario de Malaga, Malaga, Spain.
  • Department of Medical Oncology, Virgen de La Victoria University Hospital, Malaga, Spain. The Biomedical Research Institute of Malaga (IBIMA-CIMES-UMA), Malaga, Spain.
  • Faculty of Medicine, University of Malaga, Malaga, Spain.
  • Department of Medical Oncology, Virgen de La Victoria University Hospital, Malaga, Spain. The Biomedical Research Institute of Malaga (IBIMA-CIMES-UMA), Malaga, Spain. Faculty of Medicine, University of Malaga, Malaga, Spain.

Abstract

PURPOSE

Evaluate real-world outcomes in three cohorts of patients with early-stage triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC): (1) patients who achieved pathological complete response (pCR); (2) patients without pCR who didn't receive adjuvant chemotherapy; and (3) patients without pCR who received adjuvant capecitabine.

METHODS

Retrospective cross-sectional study from two hospitals in Málaga. Patients with TNBC received standard NAC followed by surgery. Between 2004 and 2015, patients not achieving pCR received no further systemic therapy. From 2015 onward, these patients were treated with adjuvant capecitabine. Kaplan-Meier and log-rank tests were used to compare disease-free survival (DFS) and overall survival (OS).

RESULTS

A total of 312 patients were included in the study. 133 achieved pCR, 84 patients didn't achieve pCR and didn't receive adjuvant capecitabine and 95 patients didn't reach pCR and received adjuvant capecitabine. 89 patients experienced recurrence and 70 patients died. Patients who achieved pCR had a significantly higher DFS (HR 0.21 CI95% 0.12-0.36, p<0.0001) and higher overall survival (HR 0.27 CI95% 0.15-0.49, p<0.0001) compared to those who didn't. Statistically significant differences in DFS and OS were observed among the three cohorts (DFS: p<0.00001; OS: p=0.00005). However, no statistically significant differences were found between cohorts 2 and 3 in terms of DFS (p=0.94) or OS (p=0.34).

CONCLUSIONS

Patients who achieved pCR had better outcomes compared to those who didn't. Among patients who didn't achieve pCR, the addition of capecitabine didn't result in significant improvements in DFS or OS compared to those who didn't receive adjuvant treatment.

MeSH

Triple Negative Breast Neoplasms, Breast Neoplasms, Neoplasms, Drug Therapy, Chemotherapy, Adjuvant, Breast, Therapeutics, Capecitabine, Data Analysis, Chemotherapy